Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2022-04-21 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
新乡拓新药业股份有限公司章程（2022年4月）
Governance Information Classification · 100% confidence The document is the Articles of Association (章程) of Xinxiang Tuoxin Pharmaceutical Co., Ltd., detailing the company's organizational structure, shareholder rights, board of directors, management, and other governance matters. It includes detailed provisions on shares, shareholder meetings, board responsibilities, and internal rules. There is no indication that this is an announcement or a summary; it is a full governance document. This matches the description of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices. The document length (15,000 characters) and content confirm it is a substantive governance report, not a brief announcement or other filing type.
2022-04-21 Chinese
关联交易决策制度
Governance Information Classification · 95% confidence The document is titled "新乡拓新药业股份有限公司 关联交易决策制度" which translates to "Xinxiang Tuoxin Pharmaceutical Co., Ltd. Related Party Transaction Decision System." It is a detailed policy document outlining the principles, definitions, procedures, and responsibilities related to related party transactions within the company. It includes sections on general principles, definitions of related parties, transaction types, pricing principles, approval and disclosure procedures, and accountability measures. The document is dated April 2022 and appears to be a governance or internal control policy rather than a financial report or announcement. It does not contain financial statements, earnings data, or voting results. It is not a report publication announcement or a certification. The content aligns with governance information detailing internal rules and procedures related to related party transactions. Therefore, the most appropriate classification is Governance Information (CGR).
2022-04-21 Chinese
对外担保管理制度
Governance Information Classification · 95% confidence The document is titled '新乡拓新药业股份有限公司 对外担保管理制度' which translates to 'Xinxiang Tuoxin Pharmaceutical Co., Ltd. External Guarantee Management System'. It is a detailed internal policy document outlining the company's procedures, principles, and rules regarding external guarantees, including decision-making authority, risk management, contract signing, and penalties. It references relevant laws and regulations but does not contain financial statements, audit results, or shareholder meeting materials. It is not an announcement or a report of financial results or governance changes. It is a governance-related internal control document focused on managing external guarantees and risks. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 4454 characters, which is sufficient for a substantive policy document rather than a brief announcement.
2022-04-21 Chinese
2021年度独立董事述职报告（闫福林）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2021, detailing the independent director's attendance at meetings, opinions on board matters, committee participation, and efforts to protect investor rights. It is a narrative report on the director's duties and activities rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it a regulatory filing or announcement of voting results. This type of document fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports on their roles and responsibilities.
2022-04-21 Chinese
2021年度独立董事述职报告（刘建伟）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2021, detailing the independent director's attendance at meetings, opinions on various board matters, committee participation, and efforts to protect investor rights. It is a narrative report on the director's duties and activities rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. This type of document fits best under Board/Management Information (MANG) as it relates to board member activities and governance roles.
2022-04-21 Chinese
2021年度独立董事述职报告（靳焱顺）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2021, detailing the independent director's attendance at meetings, opinions on various board matters, committee participation, and efforts to protect investor rights. It is a narrative report on the director's duties and activities rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. This type of document fits best under Board/Management Information (MANG), as it relates to board members' roles and activities.
2022-04-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.